569 related articles for article (PubMed ID: 30209397)
21. Primary liver tumors: origin and target therapy.
Papoulas M; Theocharis S
Expert Opin Ther Targets; 2009 Aug; 13(8):957-65. PubMed ID: 19606929
[TBL] [Abstract][Full Text] [Related]
22. Road to stemness in hepatocellular carcinoma.
Flores-Téllez TN; Villa-Treviño S; Piña-Vázquez C
World J Gastroenterol; 2017 Oct; 23(37):6750-6776. PubMed ID: 29085221
[TBL] [Abstract][Full Text] [Related]
23. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Bösmüller H; Pfefferle V; Bittar Z; Scheble V; Horger M; Sipos B; Fend F
Pathol Res Pract; 2018 Aug; 214(8):1136-1141. PubMed ID: 29935812
[TBL] [Abstract][Full Text] [Related]
24. Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model.
Li Y; Agrawal I; Gong Z
Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31515263
[TBL] [Abstract][Full Text] [Related]
25. Allelotypic characteristics of thorotrast-induced intrahepatic cholangiocarcinoma: comparison to liver cancers not associated with thorotrast.
Liu D; Wada I; Tateno H; Ogino D; Suzuki M; Li L; Lu W; Kojiro M; Fukayama M; Okabe H; Fukumoto M
Radiat Res; 2004 Feb; 161(2):235-43. PubMed ID: 14731065
[TBL] [Abstract][Full Text] [Related]
26. SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model.
Xu M; Wang J; Xu Z; Li R; Wang P; Shang R; Cigliano A; Ribback S; Solinas A; Pes GM; Evert K; Wang H; Song X; Zhang S; Che L; Pascale RM; Calvisi DF; Liu Q; Chen X
Cancer Res; 2019 Nov; 79(21):5563-5574. PubMed ID: 31383647
[TBL] [Abstract][Full Text] [Related]
27. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.
Sekiya S; Suzuki A
J Clin Invest; 2012 Nov; 122(11):3914-8. PubMed ID: 23023701
[TBL] [Abstract][Full Text] [Related]
28. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
[TBL] [Abstract][Full Text] [Related]
29. Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells.
Gailhouste L; Liew LC; Yasukawa K; Hatada I; Tanaka Y; Nakagama H; Ochiya T
Mol Ther; 2018 Jul; 26(7):1840-1854. PubMed ID: 29759938
[TBL] [Abstract][Full Text] [Related]
30. Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice.
Shin S; Wangensteen KJ; Teta-Bissett M; Wang YJ; Mosleh-Shirazi E; Buza EL; Greenbaum LE; Kaestner KH
Hepatology; 2016 Oct; 64(4):1163-1177. PubMed ID: 27099001
[TBL] [Abstract][Full Text] [Related]
31. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
[TBL] [Abstract][Full Text] [Related]
32. Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma.
Matsumoto T; Takai A; Eso Y; Kinoshita K; Manabe T; Seno H; Chiba T; Marusawa H
Cancer Res; 2017 Nov; 77(22):6131-6143. PubMed ID: 28951464
[TBL] [Abstract][Full Text] [Related]
33. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
[TBL] [Abstract][Full Text] [Related]
34. Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2.
Stefanska B; Suderman M; Machnes Z; Bhattacharyya B; Hallett M; Szyf M
Carcinogenesis; 2013 Dec; 34(12):2738-49. PubMed ID: 23955541
[TBL] [Abstract][Full Text] [Related]
35. Microtubule associated protein 9 inhibits liver tumorigenesis by suppressing ERCC3.
Zhang J; Huang JZ; Zhang YQ; Zhang X; Zhao LY; Li CG; Zhou YF; Wei H; Yu J
EBioMedicine; 2020 Mar; 53():102701. PubMed ID: 32151798
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis.
Lu M; Hartmann D; Braren R; Gupta A; Wang B; Wang Y; Mogler C; Cheng Z; Wirth T; Friess H; Kleeff J; Hüser N; Sunami Y
BMC Cancer; 2019 Sep; 19(1):887. PubMed ID: 31488102
[TBL] [Abstract][Full Text] [Related]
37. Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) originating from hepatic progenitor cell: a case report and review of the literature.
Hu J; Yuan R; Huang C; Shao J; Zou S; Wang K
World J Surg Oncol; 2016 Aug; 14(1):218. PubMed ID: 27535234
[TBL] [Abstract][Full Text] [Related]
38. Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations.
Kim SK; Marusawa H; Eso Y; Chiba T; Kudo M
Dig Dis; 2013; 31(5-6):454-8. PubMed ID: 24281020
[TBL] [Abstract][Full Text] [Related]
39. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.
Holczbauer Á; Factor VM; Andersen JB; Marquardt JU; Kleiner DE; Raggi C; Kitade M; Seo D; Akita H; Durkin ME; Thorgeirsson SS
Gastroenterology; 2013 Jul; 145(1):221-231. PubMed ID: 23523670
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
